SERPINA3 antibody
- Known as:
- SERPINA3 (anti-)
- Catalog number:
- orb94611
- Product Quantity:
- 50 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- SERPINA3 antibody
Related genes to: SERPINA3 antibody
- Gene:
- SERPINA3 NIH gene
- Name:
- serpin family A member 3
- Previous symbol:
- AACT
- Synonyms:
- ACT
- Chromosome:
- 14q32.13
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-04
Related products to: SERPINA3 antibody
Related articles to: SERPINA3 antibody
- Neuroblastoma (NB) is one of the most common malignant tumors in children. Despite intensive multimodal treatments, patients with high-risk NB still have a poor prognosis; therefore, early identification of high-risk patients based on reliable NB biomarkers is essential. Endoplasmic reticulum (ER) stress has been demonstrated to play a vital role in cancer biology; however, it is unclear whether ER stress-related genes are involved in NB and should be further explored as new potential diagnostic and prognostic targets. - Source: PubMed
Publication date: 2026/03/24
Lu WentingZhou RuixiYue YanYing JunjieXiong TaoTang JunShi JingWang HuaZhang LiRuan Tiechao - Tamoxifen (TAM) resistance remains a challenge in estrogen receptor-positive breast cancer treatment. Current research suggested that mesenchymal stem cells (MSCs) derived exosomes may mediate chemoresistance, but the underlying mechanisms are unclear. This study investigates how exosomes from tamoxifen-pretreated MSCs (Tt-MSC-exos) promote tamoxifen resistance through the miR-137/SERPINA3 axis. - Source: PubMed
Publication date: 2026/05/21
Huang XiaolanLi TingtingYe ShiqianLan YananZeng LinLiu Yan - Major depressive disorder (MDD) in adolescents lacks objective peripheral biomarkers that may assist diagnosis and biological stratification. Serine protease inhibitor A3 (SERPINA3) is an inflammation-related acute-phase protein, but its circulating levels and clinical relevance in adolescent MDD remain unclear. - Source: PubMed
Publication date: 2026/05/20
Xue YongFan Gui MeiWang YueDong HuiWei Chun HongZhang Bo - Lung cancer remains the leading cause of cancer-related mortality, with poor outcomes driven by late presentation and therapy resistance. Although genes encoding secreted proteins may reflect tumor biology and have biomarker potential, systematic multi-cohort studies identifying and validating prognostically relevant secreted-protein candidates in non-small cell lung cancer (NSCLC) are limited. - Source: PubMed
Publication date: 2026/05/18
Kim JoonLee GeuninYong Seung-HyunKim Eun YoungJo YunjuJeong WoojuRyu DongryeolOh Chang-MyungLee Sang Hoon - Left bundle branch pacing (LBBP) has gained increasing attention as a novel pacing strategy, but its molecular underpinnings in the context of heart failure (HF) remain unclear due to limited LBBP-specific datasets.We integrated three GEO datasets (GSE5406, GSE19303, GSE21610) representing HF transcriptomics and performed batch correction, differential expression analysis, functional enrichment, immune infiltration profiling, weighted gene co-expression network analysis (WGCNA), hub gene identification, and drug-pathway prediction.PCA demonstrated successful batch correction across datasets. Differentially expressed genes (DEGs), including HOPX, NPPA, MYH6, SERPINA3, and ASPN, were identified. Enrichment analyses indicated extracellular matrix remodeling, cardiac development, and cGMP-PKG signaling. Immune analysis showed significant alterations in B cell memory, plasma cells, CD8 T cells, regulatory T cells, NK cells, monocytes, macrophages (M0/M1/M2), dendritic cells, and mast cells. WGCNA highlighted significant modules (MEpink, MElightyellow, MEyellow, MEgreenyellow) associated with treatment response. Hub gene analysis confirmed ASPN, HOPX, MYH6, SERPINA3, and NPPA as key drivers. Drug prediction suggested multiple candidates, including β-blockers, RAAS inhibitors, anti-fibrotic agents, vericiguat, metformin, and SGLT2 inhibitors.This integrative analysis of HF transcriptomics reveals potential immune remodeling, hub genes, and repurposable drugs relevant to LBBP response heterogeneity, providing hypothesis-generating insights and potential therapeutic strategies for validation in LBBP-specific cohort. - Source: PubMed
Publication date: 2026/05/11
Sun XiaTang XiangZhong WeiYuan WeiJin Mingfeng